Early Advice Crucial For Navigating Denmark’s New Appraisal System
Executive Summary
Denmark is moving to a QALY based evaluation system for hospital drugs. Despite a more complex process, the change could still mean quicker market access, says the pharmaceutical industry.
You may also be interested in...
Denmark To Adopt QALY For Cost-Effectiveness Assessments
Using the QALY is expected to help the Danish Medicines Council make its decisions on the cost effectiveness of drugs more transparent, but it will also extend the time the council takes to make a recommendation.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.